MEI Pharma to acquire S*BIO’s Pracinostat

Wednesday, August 8, 2012

MEI Pharma, a San Diego-based oncology company, has entered into a definitive asset purchase agreement with S*BIO, a privately held biotech in Singapore, to acquire S*BIO’s exclusive worldwide rights to Pracinostat, an investigational, potential best-in-class, oral histone deacetylase (HDAC) inhibitor.

[Read More]

S*BIO to initiate phase III myelofibrosis trial

Tuesday, October 25, 2011

S*BIO plans to initiate a global phase III clinical program of its novel JAK2 inhibitor pacritinib (SB1518), in the first half of 2012 to further demonstrate its activity and tolerability for the treatment of myelofibrosis (MF). The company is actively exploring partnering opportunities for the advancement of its leading JAK2 program.

[Read More]

S*BIO reforms collaboration with Onyx

Wednesday, May 4, 2011

Sinapore-based S*BIO will restructure its collaboration and option agreement with California-based Onyx Pharmaceuticals, which the companies entered into in January 2009. As a result of the restructuring, S*BIO has regained North American and European rights to its novel JAK2 inhibitors, SB1518 and SB1578, from Onyx.  Following a successful and productive partnership with Onyx, S*BIO will now be in a position to drive the development of its lead JAK2 program independently.

[Read More]

Singapore develops its first cancer drug

Thursday, March 17, 2011

Singapore has developed its first cancer drug, SB-939, from two Singapore-based cancer institutes and a biotechnology company, S*BIO, according to Channel News Asia.   The Singapore National University Cancer Institute, the Cancer Institute of Singapore and S*BIO have collaborated for the phase I trials.

[Read More]